AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1516877
Drug: Remefa S
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remefa S (glycyrrhizinic acid), administered three times a week for 12 months
Trial: 6148361
Drug: ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (300 mg/day)
Trial: 6148361
Drug: cimetidine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cimetidine (1200 mg/day)
Trial: 28407661
Drug: Saxagliptin 5
RxNorm normalized name: sAXagliptin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin 5 mg per day for 12 weeks
Trial: 28407661
Drug: Metformin 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1,500 mg per day for 12 weeks
Trial: 16025958
Drug: Compound Duzhong
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Duzhong Jiangu granule (CDJG)
Trial: 16025958
Drug: Zhuanggu Guanjie
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhuanggu Guanjie pill (ZGP)
Trial: 14504154
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural analgesia (TEA) with bupivacaine (0.25% during operation, 0.125% after operation) and fentanyl (2 microg ml(‐1))
Trial: 31608608
Drug: Postoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotics prescribed for 44% of the extractions
Trial: 31608608
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative antibiotics prescribed
Trial: 27846058
Drug: Investigational hexavalent
RxNorm normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational hexavalent vaccine (HV)
Trial: 19765505
Drug: Participants compared
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants compared to NSW adult daily smokers
Trial: 17577495
Drug: Tramadol preoperative,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol preoperative, 100 mg IM 1 hour before surgery (group A)
Trial: 17577495
Drug: Tramadol postoperative,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol postoperative, 100 mg IM immediately after surgery (group B)
Trial: 11740320
Drug: RRV-tetravalent vaccine
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRV-tetravalent vaccine
Trial: 9973803
Drug: Oxatomide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (1 mg/kg/day) in one evening dose
Trial: 9973803
Drug: Oxatomide (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (1 mg/kg/day) divided into two administrations
Trial: 9973803
Drug: Oxatomide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (2 mg/kg/day) after dosage increase
Trial: 29445912
Drug: Pan-fried beef
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pan-fried beef steak (270±20 g)
Trial: 29445912
Drug: Sous-vide beef
RxNorm normalized name: Beef
DrugBank: Beef (DB10509)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sous-vide beef steak (270±20 g)
Trial: 8918410
Drug: Bicalutamide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide (50 mg once daily) plus LHRH analogue therapy (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Trial: 8918410
Drug: Flutamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (250 mg three times daily) plus LHRH analogue therapy (goserelin acetate 3.6 mg every 28 days or leuprolide acetate 7.5 mg every 28 days)
Trial: 6211327
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide (0.16 mg by pressurized inhaler; 1 mg nebulized)
Trial: 6211327
Drug: Salbutamol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (0.8 mg by pressurized inhaler; 5 mg nebulized)
Trial: 30393868
Drug: Low-Intensity Pulsed
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Pulsed Ultrasound (LIPUS) therapy applied bilaterally for 20 minutes daily for the first 10 days and thereafter at least 3 times per week until complete mandibular advancement was achieved.
Trial: 30393868
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LIPUS therapy).
Trial: 23236345
Drug: Weekly standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly standardized motivational text message
Trial: 11394244
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (300 mg alpha‐tocopherol daily)
Trial: 9608882
Drug: Fast Melting
RxNorm normalized name: CVS Motion Sickness Fast Melting 25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast Melting Tablet (FMT)
Trial: 9608882
Drug: Sugar Coated
RxNorm normalized name: TIOPRONIN 100 mg ORAL TABLET, SUGAR COATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Coated Tablets (SCT)
Trial: 8015023
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms of recombinant yeast‐derived HBV vaccine
Trial: 8015023
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms of recombinant yeast‐derived HBV vaccine
Trial: 3050522
Drug: Aspirin (325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (325 mg twice daily)
Trial: 3050522
Drug: Heparin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (1000 units per hour by intravenous infusion)
Trial: 3050522
Drug: Aspirin plus
RxNorm normalized name: Aspirin Plus Antacid Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin plus Heparin
Trial: 28574158
Drug: Whitening microneedle
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whitening microneedle patch
Trial: 18289446
Drug: Intraoperative intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous tramadol 2 mg kg(‐1)
Trial: 18289446
Drug: Placebo (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (30 mL saline)
Trial: 16494982
Drug: Ground linseeds
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ground linseeds (20 g/d) for 2 months
Trial: 12559660
Drug: Chromium picolinate
RxNorm normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chromium picolinate (600 micro g for 8 weeks)
Trial: 11038077
Drug: rhuMAb CD18
RxNorm normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rhuMAb CD18 (2 mg/kg)
Trial: 11038077
Drug: rhuMAb CD18
RxNorm normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rhuMAb CD18 (1 mg/kg)
Trial: 11038077
Drug: rhuMAb CD18
RxNorm normalized name: rhuMAb 2H7
DrugBank: Ocrelizumab (DB11988)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rhuMAb CD18 (0.5 mg/kg)
Trial: 9075510
Drug: Painstop (paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Painstop (paracetamol 12 mg, codeine 0.5 mg, promethazine 0.65 mg per 1.0 ml, dosage 1.0 ml/kg)
Trial: 29266485
Drug: One-stage ridge
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage ridge augmentation with resorbable membrane (M+)
Trial: 29266485
Drug: One-stage ridge
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-stage ridge augmentation without resorbable membrane (M-)
Trial: 22246619
Drug: 400‐mg EGCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400‐mg EGCG as PPE
Trial: 22246619
Drug: 800‐mg EGCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800‐mg EGCG as PPE
Trial: 20163376
Drug: PF-03491390 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03491390 (5, 25 or 50 mg) orally twice daily for up to 12 weeks
Trial: 17905607
Drug: Resilon after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resilon after retreatment (no further treatment)
Trial: 12108617
Drug: Synthetic human
RxNorm normalized name: Synthetic human secretin
DrugBank: Secretin human (DB09532)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic human secretin (single dose)
Trial: 2136991
Drug: Low-energy gallium-arsenide
RxNorm normalized name: GALLIUM ARSENIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-energy gallium-arsenide laser treatment
Trial: 31773372
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy with a laser device that did not make active pulses
Trial: 29178842
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of pepsin and amino acid hydrochloride taken as tablets three times daily for 6 weeks
Trial: 29178842
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of pepsin and amino acid hydrochloride
Trial: 18593092
Drug: Evidence-based resources
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evidence-based resources for dentists (e.g., journals, online resources like PubMed and Cochrane Collaboration)
Trial: 17201610
Drug: Quetiapine (400-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (400-600 mg/day)
Trial: 17201610
Drug: Divalproex (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalproex (serum level 80-120 microg/mL)
Trial: 12749423
Drug: Fixed group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed group (GnRH antagonist starting on day 6 of stimulation)
Trial: 12749423
Drug: Flexible group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible group (GnRH antagonist starting when a follicle of > or = 15 mm was present)
Trial: 29910054
Drug: Adaptive servoventilation
RxNorm normalized name: ADAPT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive servoventilation (ASV) + Optimal Medical Therapy (OMT)
Trial: 20456213
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg vardenafil orodispersible tablet (ODT)
Trial: 10617943
Drug: Encapsulated fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated fish oil (1.45 g eicosapentaenoic acid and 1.55 g docosahexaenoic acid/d) for 4 weeks
Trial: 9382759
Drug: Pseudomonas aeruginosa
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine
Trial: 1554923
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg/d during five months
Trial: 3754234
Drug: piperazinedione 9
RxNorm normalized name: 2,5-piperazinedione
FDA approved: no
EMA approved: no
PMDA approved: no
Description: piperazinedione 9 mg/m2 iv every 3 weeks
Trial: 3754234
Drug: cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin 50 mg/m2 iv every 3 weeks
Trial: 30816148
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of a combination of polyphenolic extracts from Lippia citriodora L. and Hibiscus sabdariffa L. (LC-HS)
Trial: 25238909
Drug: Leucovorin 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin 0 mg/m2
Trial: 25238909
Drug: Leucovorin 60
RxNorm normalized name: leucovorin 60 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin 60 mg/m2
Trial: 25238909
Drug: Leucovorin 200
RxNorm normalized name: leucovorin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin 200 mg/m2
Trial: 25238909
Drug: Leucovorin 500
RxNorm normalized name: leucovorin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin 500 mg/m2
Trial: 22729297
Drug: Dexamethasone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (6 mg/ml)
Trial: 22729297
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline 1 ml)
Trial: 16574937
Drug: 1018 ISS
RxNorm normalized name: 1018 ISS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1018 ISS (36 mg by nebulization weekly for 4 weeks)
Trial: 14606080
Drug: Capsule oxymatrine
RxNorm normalized name: Oxymatrine
DrugBank: Oxymatrine (DB16276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule oxymatrine
Trial: 14606080
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of oxymatrine
Trial: 8881618
Drug: Alfentanil 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil 1 mg
Trial: 8881618
Drug: Lignocaine 40
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignocaine 40 mg
Trial: 31074689
Drug: Total IgG
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total IgG levels in MI subjects with MACE (24.9 mg/mL)
Trial: 31074689
Drug: Total IgG
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total IgG levels in controls (18.4 mg/mL)
Trial: 31074689
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) levels in MI subjects with MACE (1.1 mg/mL)
Trial: 31074689
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) levels in controls (1.9 mg/mL)
Trial: 30081016
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogens (CEE 0.625 mg/day)
Trial: 30081016
Drug: Oral CEE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CEE + medroxyprogesterone acetate (CEE 0.625 mg/day + MPA 2.5 mg/day)
Trial: 20551965
Drug: Salmon (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmon (3 x 150 g/week, 2.1 g LC n-3 PUFA per day)
Trial: 20551965
Drug: Cod (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cod (3 x 150 g/week, 0.3 g LC n-3 PUFA per day)
Trial: 20551965
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (1.3 g LC n-3 PUFA per day)
Trial: 8905437
Drug: Cisapride 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride 0.2 mg/kg body weight, 30 min prior to measurement of GCTT
Trial: 1678921
Drug: Terazosin 5
RxNorm normalized name: terazosin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin 5 mg
Trial: 1678921
Drug: Terazosin 10
RxNorm normalized name: terazosin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin 10 to 40 mg
Trial: 1678921
Drug: Terazosin 1
RxNorm normalized name: terazosin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin 1 to 5 mg
Trial: 7048339
Drug: 0.2% dithranol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% dithranol and urea cream
Trial: 7048339
Drug: 0.1% dithranol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% dithranol and urea cream
Trial: 30861163
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum supplement during 4 weeks of induction treatment
Trial: 30861163
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum supplement
Trial: 30861163
Drug: Placebo supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplement during 4 weeks of induction treatment
Trial: 12770854
Drug: Inhaled nitric
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nitric oxide (20 ppm NO)
Trial: 9022539
Drug: Cafestol (61-64
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cafestol (61-64 mg/d)
Trial: 9022539
Drug: Cafestol plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cafestol plus kahweol (cafestol 60 mg/d and kahweol 48-54 mg/d)
Trial: 3899033
Drug: Piracetam (1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piracetam (1600 mg 3 times a day)
Trial: 3899033
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg 3 times a day)
Trial: 3899033
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of piracetam and pentoxifylline
Trial: 26004290
Drug: Monthly information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly information bulletins and phone calls (comparison group)
Trial: 20951543
Drug: Exposure Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure Therapy Only (EXP)
Trial: 18469642
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous pantoprazole (40 mg q24 hour; 40 mg q12 hour; 80 mg q24 hour; 80 mg q12 hour; 80 mg q8 hour)
Trial: 18469642
Drug: Continuous cimetidine
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous cimetidine infusion (300 mg bolus; 50 mg/h)
Trial: 18469642
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (pantoprazole and cimetidine)
Trial: 16531895
Drug: Carbohydrate and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate and protein hydrolysate (CHO-PRO: 0.8 g.kg.h carbohydrate and 0.4 g.kg.h protein)
Trial: 16531895
Drug: Carbohydrate, protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate, protein hydrolysate, and free leucine (CHO-PRO-LEU: 0.8 g.kg.h carbohydrate, 0.4 g.kg.h protein, and 0.1 g.kg.h leucine)
Trial: 16531895
Drug: Carbohydrate (CHO:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate (CHO: 0.8 g.kg.h)
Trial: 3173919
Drug: Vaginal bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal bromocriptine 2.5 mg
Trial: 3173919
Drug: Vaginal bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal bromocriptine 5.0 mg
Trial: 3173919
Drug: Vaginal bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal bromocriptine 7.5 mg
Trial: 3173919
Drug: Oral bromocriptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral bromocriptine 2.5 mg
Trial: 25802434
Drug: Mass test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass test and treatment (MTAT) intervention; three rounds; details on dosage and duration not specified.
Trial: 20352370
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg magnesium per kilogram body weight (Group 1 - sedentary controls)
Trial: 20352370
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg magnesium per kilogram body weight (Group 2 - tae kwon do athletes)
Trial: 20352370
Drug: No magnesium
RxNorm normalized name: DPBS 1X, NO CALCIUM, NO MAGNESIUM
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No magnesium supplements (Group 3 - tae kwon do athletes)
Trial: 9036801
Drug: Cyclophosphamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide plus testosterone (100 mg intramuscularly every 15 days)
Trial: 9036801
Drug: Cyclophosphamide (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (oral and intravenous) without testosterone
Trial: 31780004
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) bundle therapy combined with conventional treatment for sepsis and AGI
Trial: 31780004
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received conventional treatment for sepsis and AGI
Trial: 29482973
Drug: Standardised intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised intravenous hydration with high dose sodium bicarbonate (1 mL/kg of 8.4% NaHCO3)
Trial: 29482973
Drug: Standardised intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised intravenous hydration without sodium bicarbonate (control)
Trial: 27095791
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy + depressive relapse active monitoring
Trial: 24609624
Drug: Multiple intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intravitreal injections of anti-VEGF (more than three injections) in DMR patients
Trial: 24609624
Drug: Multiple intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intravitreal injections of anti-VEGF (more than three injections) in RVO patients
Trial: 23084093
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (sulfadoxine/pyrimethamine FDC tablet, 1500/75 mg)